Lefamulin or moxifloxacin for community-acquired pneumonia - balancing innovation, safety, and evidence

Sep 29, 2026

Uploaded by kopisore

Recent approval of lefamulin provides an oral and intravenous alternative to fluoroquinolones for community-acquired bacterial pneumonia. Pooled and investigator-led trials report lefamulin as noninferior to moxifloxacin with comparable safety and sustained efficacy, including activity against typical and atypical pathogens, even among selected resistant strains. Safety differentiation centers on fewer fluoroquinolone class concerns but requires attention to gastrointestinal events and QT-interval–related cautions. Adoption depends on cost, local resistance, and further head-to-head evidence.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Abstract

Letter to the Editor

Evidence comparing lefamulin and moxifloxacin

Mechanistic and microbiological activity

Safety and tolerability considerations

Barriers and clinical adoption strategy

Conclusion

Letter to the Editor Lefamulin or moxifloxacin for community-acquiredpneumonia: balancing innovation, safety, andevidence Saad Arsalan Wasti, MBBSa , Areesha Wasti, MBBSb , Muhammad Usman Iqbal, MBBSa , Naseeb Danaf, MDc ,* # Abstract The recent approval of lefamulin presents an alternative to fluoroquinolones for community-acquired pneumonia. In recent trials,lefamulin matched moxifloxacininearly clinical response and safety, with a favorable activity spectrum including atypical patho -gens. However, fluoroquinolones remain entrenched due to cost, clinician familiarity, and broad guidelines. This letter examinescurrent evidence comparing the two, highlights potential niches forlefamulin, and calls for more trials to guide adoption in diversehealthcare settings. Keywords: clinical awareness, lefamulin, moxifloxacin, pneumonia Dear Editor, The recent approval of Lefamulin (Xenleta), a systemic pleur -omutilin, for community-acquired bacterial pneumonia (CABP)offers clinicians a novel oral and intravenous option to treat thiscondition[1] . Since the Lefamulin Evaluation Against Pneumonia(LEAP) trials (LEAP-1 and LEAP-2), Lefamulin has been posi -tioned as a noninferior alternative to the respiratory fluoroquino -lone Moxifloxacin, but important questions remain about whereLefamulin should sit in everyday practice compared with the well -known, inexpensive, and widely available Moxifloxacin. In a recently published pooled analysis of the LEAP-1 and LEAP-2 trials, along with the LEAP China trial, Lefamulin was found to benon-inferior to Moxifloxacin for CABP. It showed sustained highefficacy with comparable safety profiles[2] . In addition, more recentinvestigator-led randomized work from the Middle East reportsLefamulin to be noninferior to Moxifloxacin in hospitalizedpatients with higher-risk disease (PSI class III or higher)[3] . Thisrecent evidence has the potential to broaden Lefamulin’s potentialutility beyond the outpatient or lower-severity populations. Mechanistically and microbiologically, Lefamulin’s targetedinhibition of bacterial protein synthesis confers potent in vitroactivity against both typical CABP pathogens (Streptococcus aDepartment of Medicine, King Edward Medical University, Lahore, Pakistan,bDepartment of Medicine, Continental Medical College, Lahore, Pakistan andcFaculty of Medical Sciences, Lebanese University, Beirut, LebanonSponsorships or competing interests that maybe relevant to content are disclosedatthe end of this article. *Corresponding author. Address: Faculty ofMedical Sciences, Lebanese University,Beirut 1101, Lebanon. Tel.:+961 71164810. E-mail: naseeb.danaf@st.ul.edu.lb(N. Danaf). Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is anopen access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where itis permissible todownload and share the work provided itis properly cited. The work cannot bechanged in any way or used commercially without permission from the journal. Annals of Medicine & Surgery (2026) 88:1001–1002Received 17 October 2025; Accepted 5 November 2025Published online 22 November 2025http://dx.doi.org/10.1097/MS9.0000000000004342 pneumoniae, Haemophilus influenzae) and atypical organisms(such as Mycoplasma), including many macrolide- and somefluoroquinolone-resistant strains, suggesting a useful rolewhere atypicals are suspected or fluoroquinolone resistance isa concern[4] . Safety and tolerability are central to choosing an alternative tofluoroquinolones. Lefamulin’s adverse event profile in trials wasgenerally comparable to Moxifloxacin, although gastrointestinaleffects (nausea, diarrhea) were reported more frequently withLefamulin in some cohorts. Importantly, Lefamulin usage avoidscertain fluoroquinolone-class adverse-event concerns (tendinopa -thy, known rare but serious neuro- and vascular risks) that haveled regulators to tighten fluoroq

FAQs

What is the main purpose of the letter?

To compare the evidence for lefamulin versus moxifloxacin in community-acquired pneumonia, highlighting safety, efficacy, and potential clinical niches for adoption.

How do trial results compare lefamulin with moxifloxacin?

Pooled analyses and randomized work describe lefamulin as noninferior to moxifloxacin for community-acquired bacterial pneumonia, with comparable safety profiles and sustained efficacy.

What safety factors influence the choice between the two drugs?

Lefamulin generally matches moxifloxacin’s adverse event profile but may cause more gastrointestinal effects in some cohorts, while also avoiding certain fluoroquinolone-class risks; however, QT interval–related precautions remain important.

Sep 29, 2026

Uploaded by kopisore